Ivor MacLeod
Net worth: 42 556 $ as of 31/05/2026
Net worth: 42 556 $ as of 31/05/2026
Ivor MacLeod is currently Chief Financial Officer at SCYNEXIS, Inc. since 2022.
Formerly, Mr. MacLeod was Chief Financial & Accounting Officer at Athersys, Inc. from 2021 to 2022, Chief Financial & Compliance Officer, SVP at Eisai, Inc. from 2015 to 2018, Vice President-Finance at Merck & Co., Inc. from 2012 to 2015, and Vice President-Finance & Information Technology at Hoffmann-La Roche, Inc. Education includes undergraduate studies at the University of St. Andrews.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SCYNEXIS, INC. 0.08% | 01/04/2026 | 60,363 ( 0.08% ) | 42 556 $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| SCYNEXIS, INC. | Director of Finance/CFO | 24/10/2022 |
| Companies | Position | End |
|---|---|---|
| ATHERSYS, INC. | Director of Finance/CFO | 30/06/2022 |
Eisai, Inc.
Eisai, Inc. Pharmaceuticals: MajorHealth Technology Manufacturers pharmaceutical products | Director of Finance/CFO | 01/01/2018 |
| MERCK & CO., INC. | Director of Finance/CFO | 01/01/2015 |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Director of Finance/CFO | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 7 |
|---|---|
Merck & Co., Inc.
Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Health Technology |
Eisai, Inc.
Eisai, Inc. Pharmaceuticals: MajorHealth Technology Manufacturers pharmaceutical products | Health Technology |
SCYNEXIS, Inc.
SCYNEXIS, Inc. Pharmaceuticals: MajorHealth Technology Develops novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections | Health Technology |
University of St. Andrews
University of St. Andrews Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Athersys, Inc.
Athersys, Inc. BiotechnologyHealth Technology Operates as biotechnology company that develops novel and proprietary therapies | Health Technology |
Eller College of Management
Eller College of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Select your edition
All financial news and data tailored to specific country editions